← Back to Search

0.5% Ropivacaine for Hip Arthritis (HIPFIB Trial)

Phase 2 & 3
Waitlist Available
Research Sponsored by Sunnybrook Health Sciences Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients aged 18-75, ASA I-III scheduled to undergo unilateral total hip arthroplasty.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up every 4 hours after arrival in post-operative care unit for 24 hours
Awards & highlights

HIPFIB Trial Summary

Total hip replacement (THR) is a common and major surgical procedure performed in elderly patients with significant comorbidities. Optimizing a patient's anesthetic and analgesic modalities could play a significant role in minimizing the risk of adverse events in the perioperative period and potentially shorten time to discharge and recovery. Establishing a safe and effective post-operative analgesic plan is of central importance to successful THR anesthesia care. The application of ultrasound visualization has improved the efficacy of the fascia iliaca compartment block (FICB). However, ultrasound-guided suprainguinal FICB has not yet been evaluated clinically in a large trial as a method of providing post-operative analgesia following THR. The investigators hypothesize that by performing the suprainguinal fascia iliaca block with ultrasound, it will be possible to achieve superior and more reliable analgesia in the first 24 hours than without a block.

Eligible Conditions
  • Hip Arthritis

HIPFIB Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

HIPFIB Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~every 4 hours after arrival in post-operative care unit for 24 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and every 4 hours after arrival in post-operative care unit for 24 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Opioid Consumption at 24 hours after arrival in post-operative care unit
Secondary outcome measures
Nausea
Pain Scores
Pruritus
+2 more

HIPFIB Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: 0.5% RopivacaineActive Control1 Intervention
Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls 0.5% ropivacaine.
Group II: Normal SalinePlacebo Group1 Intervention
Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls normal saline.

Find a Location

Who is running the clinical trial?

Sunnybrook Health Sciences CentreLead Sponsor
656 Previous Clinical Trials
1,550,489 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~20 spots leftby Apr 2025